A Day in the Life of a Nephrologist: 2021 NephCure Patient Summit April 20, 2021 by Kylie Karley Have you ever wondered what it might be like to walk in a kidney specialists’ shoes for a day? Get a rare peek ‘behind the curtain’ and hear from actual nephrologists about their perspective on treating rare kidney patients, some of their daily challenges, and tips for making the most of your appointments. Join us Sunday, May 16th from 12-4pm ET for the 2021 NephCure Patient Summit. During this FREE virtual gathering of patients from around the globe, you’ll hear about the latest in research and treatments and learn about your disease. You’ll also have the opportunity to directly ask our experts questions and participate in interactive community roundtables. The “Day in the Life of a Nephrologist” panel will feature Drs. Jason Cobb, Michelle Rheault, and Suneel Udani. The Patient Summit will also offer you the chance to hear from other NephCure specialists, NephCure staff, and regional volunteer leaders. Meet the Panelists: Dr. Jason Cobb is an assistant professor of medicine in the Emory University Division of Renal Medicine. Dr. Cobb is a graduate of Morehouse College with a BS in biology. He holds a medical degree from Emory University School of Medicine and completed his internal medicine residency and nephrology fellowship at Emory University. He is board-certified in internal medicine and nephrology. He sees patients in nephrology clinic at Emory University Hospital Midtown in the Medical Office Tower seeing patients with nephrology complaints such as chronic kidney disease due to diabetes, hypertension, vascular disease, and glomerulonephritis. Also, Dr. Cobb takes care of hemodialysis patients at Emory Dialysis Greenbriar and Emory Dialysis Northside, and home dialysis patients at Emory Dialysis Northside. He also rounds on inpatient services at Emory University Hospital Midtown and Emory University Hospital. Research and teaching interests include quality improvement and nephrology fellow clinic at Grady Memorial Hospital. Dr. Michelle Rheault is a board certified pediatric nephrologist and Associate Professor of Pediatrics. She completed her Pediatric Nephrology fellowship at the University of Minnesota in 2006 followed by a research fellowship at Mount Sinai School of Medicine in New York City. She joined the faculty at the University of Minnesota in 2008 and is currently the Director of the Division of Pediatric Nephrology and Medical Director of the Pediatric Dialysis unit. She is on the steering committee of the Pediatric Nephrology Research Consortium, a clinical research network that aims to facilitate collaboration in pediatric nephrology. Her clinical and research interests include Alport syndrome and other genetic kidney diseases, pediatric glomerular disease, and pediatric end stage kidney disease. Dr. Suneel Udani is a native of Chicago’s western suburbs. He joined Advanced Renal Care in July 2011. He completed his undergraduate, Master’s in Public Health, and medical school degrees at Northwestern University and went on to do his Internal Medicine training at the University of Chicago and the University of Pittsburgh. He served as a Chief Medical Resident at Cook County Hospital prior to returning to the University of Chicago for his fellowship in Nephrology. Dr. Udani is the author of multiple peer-reviewed journal articles and has presented his research at national conferences and is the author of multiple text book chapters on diagnosis and management of kidney disease. His focus is on glomerular disease and heart-kidney interactions. He is also a clinical investigator for community-based renal research program and a dedicated educator and advocate for patients with kidney disease. To learn more about the 2021 NephCure Patient Summit, including a full list of speakers, and full event agenda, click here.
NephCure Kidney International and HEAL Collaborative Partner to Launch Health Equity Initiative March 9, 2021 by Kylie Karley Initiative seeks to create interventions to prevent kidney failure and improve access to kidney disease research, care for communities of color King of Prussia, PA – March 9, 2021 – Today, NephCure Kidney International (NephCure) announced the formal launch of its Health Equity Initiative, focused on addressing access to research and care for diverse families living with chronic, protein-spilling kidney diseases, together with the Health Education Advocacy and Learning, Inc. (HEAL Collaborative) not-for-profit organization. The goal of this initiative is to improve patient outcomes by identifying solutions to strengthen the participation of underrepresented individuals in the kidney disease patient and medical arena. The initial focus will be on kidney disease in Black Americans, given the prevalence of Chronic Kidney Disease (CKD) and Focal Segmental Glomerulosclerosis (FSGS) in this population. This initiative is made possible through grant support from Travere Therapeutics, a founding partner of the Health Equity Initiative. Additional support has been provided by Mallinckrodt Pharmaceuticals and other key partners. “We are so eager to finally begin doing this important work,” said Joshua Tarnoff, NephCure CEO. “This community of patients has been neglected for too long. With so many new potential options available in trials, some specifically targeting genetic causes of kidney disease within Black communities, as well as the genetic testing now available to detect these variances, we now have a clear path forward to improve health outcomes for all patients.” More than 1 in 7 adult Americans have some form of CKD. One of the most common and aggressive sub-types of CKD is FSGS, characterized by protein in the urine, kidney scarring, and having the potential to cause relatively rapid decline in kidney function. As there are currently no FDA-approved drugs for FSGS, patients may progress to kidney failure, dialysis, and kidney transplant. CKD and FSGS disproportionally affect Black Americans at rates at least 4 times greater than white Americans. Black Americans comprise 13.2% of the United States population but represent more than 35% of all patients in the US receiving dialysis for kidney failure. In particular, a variation on the APOL1 gene often found in people of West African descent is thought to be associated with one of the most severe forms of kidney disease. Its presence indicates a significant reduction in already limited treatment options. Approximately one third of FSGS cases in the United States are thought to be associated with APOL1 variants. A key partnership within the Health Equity Initiative will be led by HEAL Collaborative, a community-based organization that focuses on working with under-served minority populations on the availability of healthcare-related services, accessibility to emerging treatment options, and consequential community benefit impact. “HEAL Collaborative’s vision of ‘Communities of Color are Healthy’ drives our mission: to develop healthy communities of color, we use our collaborative relationships, innovation, community action, and public advocacy,” said Howard Mosby, HEAL Collaborative co-founder and Treasurer. “This partnership with NephCure Kidney International aligns with our organization’s goals to build collaborative networks nationally; to establish faith-based partnerships; to hold educational sessions on innovative healthcare solutions around chronic diseases affecting morbidity and mortality in communities of color; all in partnership with policymakers, faith leaders, and community advocates.” During the 12-month pilot period of this initiative, HEAL Collaborative will engage faith-based community networks in Atlanta, GA and Chicago, IL to raise awareness of CKD and APOL1-related FSGS and provide opportunities to connect with patient advocates and disease specialists. NephCure will concurrently launch a marketing campaign to raise awareness of the genetic causes of kidney disease in people of African descent, provide patient-focused educational materials and guidance on seeking specialized care and gaining access to clinical trials, and strengthen outreach to nephrologists to aid in providing accurate and timely FSGS diagnoses. “What makes this initiative different is our focus on creating action-oriented, meaningful, and measurable change in these communities in the near-term,” said Tarnoff. “We will take what we learn from this pilot period and expand our programs in the future to reach more at-risk individuals within communities of color.” “We want to put interventions in place to reach people before they show up in the emergency room with kidney failure,” added Mosby. “We have said time and time again: No more dialysis. We must give people every opportunity to save their kidneys and remove dialysis from the conversation as a foregone conclusion.” NephCure and HEAL Collaborative have appointed a steering committee of leaders with expertise in rare kidney disease research and care, government and local advocacy, and community-based engagement to guide the Health Equity Initiative. Health Equity Steering Committee members include: Linda Goler Blount, MPH, Black Women’s Health Imperative Jason Cobb, MD, Emory University Division of Renal Medicine Roslyn Daniels, Black Health Matters Patrick O. Gee Sr., PhD, iAdvocate Inc. Keisha Gibson, MD, MPH, University of North Carolina Wanda H. Moore, JD, MEd, New Jersey Urban Peace Building Project Kevin Mott, NephCure Kidney International Quin Taylor, Tayloring Gratitude Melissa West, American Society of Nephrology Both NephCure Kidney International and HEAL Collaborative are committed to long-term sustainable improvement in care for people of color living with kidney disease. This first step is one in a long series of programs and an iterative learning process, until we collectively see equal care for patients. For partnership inquiries and to support this growing effort, please contact NephCure at research@NephCure.org. ### About NephCure Kidney International NephCure Kidney International’s mission is to accelerate research for effective treatments for rare forms of Nephrotic Syndrome, and to provide education and support that will improve the lives of those affected by these protein-spilling kidney diseases. Founded in 2000 by a group of committed patient parents, NephCure has invested more than $40 million in kidney disease research and helped create a landscape where there are now nearly 30 interventional drug trials for primary glomerular kidney diseases. NephCure is a U.S. tax exempt 501(c)(3) public charity. For more information, please visit www.NephCure.org. About HEAL Collaborative HEAL is a not-for-profit community-based organization that focuses on Educating, Informing, Advocating and Engaging under-served minority populations on the availability of healthcare-related services, accessibility to emerging treatment options, and consequential community benefit impact. For more information, please visit www.HEALCollaborative.org. ## Media Contact Lauren Eva, Director of Marketing & Communications 610-540-0186 x21 Lauren.Eva@NephCure.org
American Society of Nephrology Leads Efforts to Advance Equitable Distribution of Covid-19 Vaccines to Dialysis Patients March 1, 2021 by Kylie Karley Newswise — Washington, DC (February 25, 2021) —The American Society of Nephrology (ASN) is spearheading efforts to secure direct federal allocation of COVID-19 vaccines to dialysis patients and frontline dialysis workers. This allocation would improve access for a vulnerable patient population, more than half of whom are Black, Hispanic, Asian, Native American, and Native Hawaiian or other Pacific Islanders (NHPIs). Forty-five organizations are urging the Biden-Harris Administration to address this public health crisis by facilitating COVID-19 vaccine allocation to all dialysis patients and frontline health workers in dialysis units. “Today we are urgently calling on the Biden-Harris Administration to provide a federal allocation of COVID-19 vaccine for people with kidney failure receiving dialysis and for the frontline healthcare workers in the dialysis facilities. Patients with kidney failure are some of the most vulnerable to COVID due to their many co-morbidities. Kidney diseases and COVID both disproportionately impact people of color, so a direct vaccine allocation would both save lives and address racial injustice at the same time. This is a critical moment in this public health battle, and people receiving dialysis need this commitment to healthcare and equity said,”. Susan E. Quaggin, MD, FRCP(C), FASN, President, ASN. People on dialysis need urgent access to COVID-19 vaccines People on dialysis are extremely susceptible to the effects of COVID-19, with COVID-associated mortality exceeding 20%, comparable to or even higher than COVID-associated mortality in long-term care facilities. (1) Ninety percent of dialysis patients receive in-center treatment three times a week for three to four hours each day. Since mid-November 2020, the kidney care community has been prepared to distribute and administer COVID-19 vaccinations quickly and safely. Most patients on dialysis have multiple co-morbidities, are more vulnerable to infection, and are unable to safely go to a separate vaccination center or pharmacy and wait in line. Dialysis organizations are highly experienced vaccinating patients for seasonal flu and are prepared to vaccinate patients for COVID-19 at this time. Providing a direct federal allocation of COVID-19 to dialysis centers enhances trust and confidence in the safety and efficacy of the vaccine, as it will be delivered in a known environment by healthcare professionals with whom patients have longstanding relationships of trust. In advance of this much-needed allocation, the 45 organizations also encouraged the federal government to urge states to prioritize dialysis patients and staff in their vaccine allocation protocols. COVID-19 and health equity are paramount issues affecting Americans with kidney diseases and the health professionals who care for them. Tackling these challenges will help improve the health of all Americans. Read the full letter here. (1) Sim JJ, et al. COVID-19 and survival in maintenance dialysis. Kidney doi: 10.1016/j. xkme.2020.11.005;
March is National Kidney Month March 1, 2021 by Lauren Eva In celebration and recognition of National Kidney Month, we’re devoting this period to sharing stories, research news, and educational opportunities specifically for communities of color and other diverse and underrepresented groups who are affected by rare, protein-spilling kidney diseases. Our focus now and always is on keeping kidneys healthy for all the members of our rare disease community. Please read our recent press release on the launch of our Health Equity Initiative, in partnership with HEAL Collaborative. Don’t miss these upcoming events: Thursday, March 4 at 7pm ET: “Rare Kidney Disease Requires Rare Expertise” – In partnership with Black Health Matters and with support from Travere Therapeutics Thursday, March 25 at 7pm ET: “Living Your Best Life with FSGS Kidney Disease” – In partnership with Black Health Matters and with support from Travere Therapeutics Check out some patient stories: Aries Merritt – Overcoming Hurdles Briana’s Journey with FSGS Finding the Beauty in Kidney Disease: Keyaira’s Story Fourth Doctor is the Charm: Kevin’s Journey to the Correct Diagnosis Sabrina’s Journey with Minimal Change Disease Stephanie’s Journey with Nephrotic Syndrome Get up to speed on the latest education, research, and commentary: An Inside Look: Vertex’s Study in APOL1-FSGS APOL1 FSGS Kidney Disease Fact Sheet Ask the Expert: Dr. Rasheed Gbadegesin The Genetic FSGS Discovery Trailblazing Possible Kidney Disease Treatment NephCure U: APOL1 with Dr. Jeffrey Kopp Make sure to visit our Facebook page to see more resources and information, including our “The Doctor is In” social media campaign.
NephCure Breaks Down Travere’s Interim FSGS DUPLEX Results February 11, 2021 by Kylie Karley NephCure’s Nurse Kristen Hood and Kylie Winkler discuss Travere’s Therapeutics achievement of interim proteinuria endpoint in the ongoing Phase 3 DUPLEX study of Sparsentan in Focal Segmental Glomerulosclerosis (FSGS). Learn more about the trial currently underway, why this is such a crucial step for patients with rare kidney diseases, and what potential treatments this could lead to in just a few short years! Read the full press release here.
Super Bowl Turkey Chili: A Chef Sachet Low-Sodium Recipe February 4, 2021 by Kylie Karley Come Sunday, many of us will be gathered around the television watching the Tampa Bay Buccaneers and the Kansas City Chiefs battle it out in Super Bowl LV. Whether you’re there for the football or just for the snacks, we have you covered with a delicious, low-sodium game-day meal your entire family will love. We’ve previously introduced you to Chef Sachet, a private chef based out of Detroit whose son was diagnosed with FSGS. This recipe follows a low-sodium diet. Her Super Bowl Turkey Chili recipe is below. To check out her other recipes, click here. Super Bowl Turkey Chili (Low-Sodium) Prep Time: 30 minutes Cook time: 2 hours Serves: 4 Ingredients: 1 sweet onion, diced 1 green bell pepper, diced 4 garlic cloves, minced ½ jalapeño, minced 2 lbs. lean ground turkey, cooked and drained 14 oz or 1 large no salt added can stew tomatoes 1 ½ tbsp ground cumin 1 tbsp paprika 1 tbsp chili powder 1 tbsp black pepper 1 cup cheddar cheese ½ cup chopped green onions For more spice, add jalapeño (optional) Instructions: Sauté onion, garlic, bell pepper and jalapeño in 2 tbsp olive oil remove from pot. Cook ground turkey and drain excess fat, add back to pot with sauteed vegetables. Add cumin, paprika, chili powder and pepper sauté for 10 minutes. Add tomatoes and let cook for 1 ½ on simmer or low heat. Once thickened and flavorful, serve with your choice of toppings! Nutrition Facts: For a real diet recipe, add chopped zucchini or squash instead of beans. They provide the same rich flavor without the phosphorus or potassium content. Cheese is high in phosphorus, if you are on a renal diet due to ESRD or Dialysis, feel free to omit the cheese from this recipe. Tomatoes are high in potassium, if you are on a full renal diet, you can leech fresh tomatoes and stew them on your own. We encourage you to talk with your doctor regarding what diet and nutritional guide is best for you to follow.
Ask the Expert: Dr. Rasheed Gbadegesin January 29, 2021 by Kylie Karley NephCure Specialist, Dr. Rasheed Gbadegesin, MD, MBBS, responds to our questions regarding genetic testing. Dr. Gbadegesin is a pediatric nephrologist at Duke University Medical Center. He is also a professor of pediatrics and professor in medicine, focusing his studies on molecular genetics of glomerular disease and genetic risk factors for childhood onset idiopathic Nephrotic Syndrome. Dr. Rasheed Gbadegesin, MD, MBBS “Why should I seek genetic testing? Nephrotic Syndrome and other rare kidney diseases are common causes of human suffering in the United States and all over the world. Nephrotic Syndrome is seen in all age groups, but it is more common in children. Nephrotic Syndrome is divided into steroid sensitive nephrotic syndrome (SSNS) and steroid resistant nephrotic syndrome (SRNS) based on response to steroid treatment. Most patients with SSNS will have excellent outcomes, while those with SRNS who are also unresponsive to other treatments may develop progressive kidney damage that will ultimately require dialysis and kidney transplantation. The cause of Nephrotic Syndrome and other kidney diseases is unknown in majority of cases. However, with the mapping of the Human Genetic Code and the development of tools to read the codes, we are now learning more about the potential causes of Nephrotic Syndrome and other kidney diseases. Using Nephrotic Syndrome as an example, we now know that a significant proportion of SRNS type are due to defects in one of 70 genes. A study from Columbia University, and other studies from the US, Canada, and Europe, showed that up to 10% of kidney disease patients with kidney disease of unknown cause have defects in one of these 70 genes and other kidney diseases genes. In addition, some genetic factors have been associated with high risk of developing kidney disease, a very good example is the association between variants in the APOL1 gene and high risk of kidney diseases in people of African ancestry. These findings are very exciting and will most likely lead to early and accurate diagnosis of different kidney diseases. They may also facilitate the identification of other diseases that may be associated with genetic kidney diseases, for example, hearing loss in people with defects in COL4A5 genes and early onset diabetes in patients with HNF1B gene defects. “Who should seek genetic testing? When in my journey is it appropriate to do so?” The simple answer is that genetic testing should be offered to those who are suspected of having genetic kidney disease, and testing should be done as soon as the diagnosis is made. For example, patients with steroid resistant nephrotic syndrome (SRNS), especially if it is associated with a history of kidney diseases in other family members, should undergo appropriate genetic testing without any delay. This approach is very important because early diagnosis of genetic SRNS will facilitate 1) tailored use of medications to reduce side effects and toxicity, 2) use of appropriate medications that are directed towards the specific genetic defect, 3) precise discussion with patients and family members on what to expect short and long term, 4) putting in place measures to prevent or slow rate of kidney damage, and 5) safe planning and timing of kidney transplantation if needed. In conclusion, genetic testing should be widely available to patients with suspected genetic kidney disease. The genetic data should be discussed with family members and experts in genetic kidney disease for accurate interpretation of results. The information from the genetic testing should be studied carefully to improve the short- and long-term outcome for the patient and other family members. If you would like to learn more about genetic testing, talk to your nephrologist and ask about the steps necessary to obtain approval from your insurance. It is important to also seek genetic counseling once the genetic testing comes back. If you are having trouble getting genetic testing approved through your insurance or your doctor is not keen on obtaining these tests, click here to learn more about obtaining your genetic testing for free through various studies or organizations.
FSGS is Now on WebMD January 25, 2021 by Kylie Karley A new educational resource is available for FSGS patients worldwide. We are proud to collaborate with WebMD/Medscape to make focal segmental glomerulosclerosis (FSGS) available as a program on the WebMD website. You can check out the brand-new information here. Within this program, you can test your FSGS knowledge, learn more about the causes of the rare protein-spilling kidney diseases, and find out about the treatment options that are available—including a deeper dive into clinical trials. This resource also includes a video from NephCure Board Member and NephCure Specialist, Dr. Kirk Campbell. He shares his expertise on the treatment options for those suffering from FSGS and breaks down the importance of enrolling in a clinical trial. We encourage you to take a look at this program on WebMD and share with family and friends to help shed light on you or your loved one’s medical condition. This program was supported by an independent educational grant from Travere Therapeutics. To learn even more about FSGS and treatment options, click here.
COVID-19 Vaccine for Kidney Patients January 13, 2021 by Lauren Eva Answers to your most frequently asked questions on COVID-19 vaccines. With new updates regarding the COVID-19 vaccine coming out regularly, it’s easy to feel overwhelmed by all the information out there. Together with our COVID-19 Medical Advisory Committee, NephCure has put together a list of answers to your most frequently asked questions when it comes to the COVID-19 vaccine and protein-spilling kidney diseases. These COVID-19 Vaccine FAQs are designed specifically with the kidney patient and caregiver in mind. This list of questions and answers is a living document, and we will continue to provide updates to them as more data and information becomes available.
The Complications of COVID-19 and Kidney Disease: Linda’s Story December 18, 2020 by Kylie Karley Written by Linda Lujan. This year, my confidence and health were greatly challenged as I faced the reality of learning that I developed a serious, potentially life-threatening disease and tested positive for COVID-19 in the same ER visit. Though I did not receive my diagnosis of Minimal Change Disease until June 24, 2020, my journey started many months prior. That’s where I’ll start my story of “Welcome to 2020.” After a flight to Texas during the week of Christmas 2019, I noticed my ankles were swollen. I thought it was due to the long flight, and I tried to relieve the swelling by elevating my legs and wearing compression socks during my weeklong stay, which helped relieve the swelling to some degree. Upon my return to Oregon, the swelling eventually resolved. As 2020 began, I was off to a great start. I was healthy and training for a half-marathon, my nutrition was on point, I was not taking any medication, and I had no underlying health conditions. Things began to change just a few weeks later. From mid-January through early March, I started gaining weight for no apparent reason. I gained a pound or so a week and couldn’t figure out why. In late February, I noticed that my legs were swollen. I started paying more attention, and though the swelling wasn’t improving, instead of thinking I had a medical issue, I thought it was related to my exercise routine. At this point, I was cycling 100+ miles every week! In mid to late March, my weight was still climbing a pound at a time, and the swelling in my legs was still prevalent. I saw my family doctor, who also thought it was related to my exercise and prescribed a diuretic. A week later there was no change, so I returned to the doctor. After seeing my albumin level in my lab results, he asked me to increase my protein intake by 20%. Within a week the swelling in my legs mostly resolved, but then my abdomen started swelling. On March 30, after a long weekend of considerable discomfort in my stomach from extreme swelling and now severe fatigue, I once again went to see my doctor. He wanted a CT scan of my belly, but because insurance was going to take three to five days to approve it, he sent me to the emergency room. There, a scan was taken of my abdomen and lungs. The ER doctor indicated that he believed I had Nephrotic Syndrome and had consulted with a nephrologist in Portland who asked that I be transferred to a hospital there. But there was one problem! The scan of my lungs revealed what was described as glass shards, which the doctor believed was an indicator I was positive for COVID-19. The doctor in Portland began working on getting me into a hospital — but special conditions were needed for my admission because he believed I was positive for COVID-19. I was transported by ambulance to Meridian Park Hospital in Portland. Upon arrival, I was taken straight to a room, bypassing what I assume would be normal procedure for a transfer. It felt a bit chaotic and I was definitely scared. My husband wasn’t allowed to be with me and would not be allowed to come see me. I was in a lot of pain, and I was processing a lot of information: what it meant to have COVID, and what in the heck Nephrotic Syndrome even was. It was a surreal and terrifying experience. After getting settled into a room, I was put on a diuretic through IV. By the next day, I was feeling much better with respect to the pressure in my abdomen. That morning, the doctor confirmed my Nephrotic Syndrome diagnosis. He said I needed a kidney biopsy to determine what specific kidney disease I had, and he also wanted an ultrasound; however, the hospital declined both orders due to coronavirus restrictions. A 24-hour urine catch was ordered, which revealed a high level of protein. The COVID-19 test came back that day as well — with a positive result. I was in the hospital for four days in a particular area that was set aside for COVID patients. At that time, there were eight patients suspected of having the virus, but I was the only confirmed positive case. What should have been a routine hospital stay (if there is such a thing) was complicated by my COVID diagnosis. I later learned from my doctor that, because he believed I had contracted COVID before it was confirmed, he fought for extreme measures for my care in addition to the coronavirus protocol the hospital already had in place. The safety protocols he asked to be implemented for my care included only one hospital doctor assigned to me, one nurse per shift allowed in my room, and meals delivered only as far as the door. Everything that came in my room was disposable, and nothing left my room. The extreme end of this caution was that during the 24-hour urine catch, I was asked to measure the urine, transfer it to a larger bag on ice, and document the measurements. I was way too sick to be managing such a task. Upon discharge from the hospital, my nephrologist informed me that I would not be able to get the biopsy until I tested negative for COVID, and, once he knew my diagnosis, treatment would not begin until I had a second consecutive negative test. Unfortunately, over the next seven weeks, I continued to test positive. The time period between my discharge from the hospital with a general diagnosis of Nephrotic Syndrome and starting treatment for it was about 12 weeks. It was a long 12 weeks! Emotionally, I was scared to death because I didn’t know what was wrong with me. The only thing I could do during that time was to research Nephrotic Syndrome — because that’s all I knew was wrong with me. It was very scary to not know my specific kidney disease diagnosis. Every positive COVID test added another level of disappointment, as it further delayed a diagnosis and treatment. This time period was stressful and emotionally challenging. I faced the reality that I had a kidney disease, but that I didn’t yet know which disease, how much damage (if any) my kidneys had suffered, and what long-term effects could result. I was concerned things would get worse as I continued to wait for a negative COVID-19 test. I finally tested negative and was able to get my biopsy in early June. On June 24, I received a diagnosis of Minimal Change Disease and started treatment of 60 mg of prednisone. My first lab results four weeks from that date revealed I was in remission, so I started to quickly taper off the prednisone. After I was released from the hospital, the nurse at the kidney center kept telling me that my doctor was fascinated by my case. I asked the PA about this, and he told me the doctor believed I had contracted COVID in late fall 2019 and that it had started attacking my kidneys when the first swelling presented in late December — causing my Minimal Change Disease. Furthermore, the doctor believed I was one of the first cases of such a diagnosis to be caused by COVID-19, and therefore a case for medical journals. At my diagnosis appointment, he told me he’d discussed my case with peers worldwide, and they were all of the belief that I was the first case in the U.S. to have had the coronavirus lead to Nephrotic Syndrome without having any underlying conditions. At the time of the kidney biopsy, my doctor asked the pathologist for an analysis for COVID to give insight to this theory, but the pathologist could not confirm it. My doctor told me that if he was right about COVID-19 causing my MCD, I would be in remission quickly, and that I would most likely have little chance of relapse. He was right. I’ve been in remission since the four-week mark, and I’m praying for no relapse. During the same appointment, he told me he was participating in a COVID/kidney case study and that he was presenting my case for it; that case study has since been published. Throughout this whirlwind year, NephCure has been amazing. When I received the initial diagnosis, I researched Nephrotic Syndrome a million and one ways. I kept changing my search words and finally came across NephCure’s Facebook group. I posted that I had a Nephrotic Syndrome diagnosis but had to wait on a biopsy because of COVID-19; a patient advocate for NephCure replied to my post and we talked on the phone a few days later. She gave me so much information and put me in contact with Kelly Helm, NephCure’s assistant director of patient advocacy. I then learned about the bi-monthly peer-to-peer video calls and started participating in them — I learned so much from the other participants on those calls, as well as from Nurse Kristen! One participant reached out to me via private message and gave me so much helpful information. Kelly kept in contact with me, and was also very supportive and responsive to my questions and/or concerns. I truly appreciated the support group and Facebook page, and the opportunity NephCure gave me to hear from people who shared similar challenges. Today, I am healthy, medicine-free, and have been back to my regular exercise routine since early September! I pray every day I stay in remission.